AEGLEA BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

Published: 2021-09-09 07:03:05 ET AGLE

Item 7.01. Regulation FD Disclosure.

On September 9, 2021, Aeglea BioTherapeutics, Inc. (the "Company") updated its corporate presentation.

A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The presentation is also available on the Company's website in the Events & Presentations section at www.aegleabio.com.

The information furnished with this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The Company dosed the first patient in the Phase 1/2 trial for AGLE-177 for the treatment of Homocystinuria in June 2021. While the Company is continuing to conduct key nonclinical activities, due to the emergence of the delta variant and the lockdowns in Australia, the Company is seeing a slowing in trial enrollment and believe this will likely impact the availability of data. As such, the Company no longer plans to provide a clinical update this year. The Company is carefully monitoring the lockdown situation in Australia as well as working with our individual trial sites to manage local COVID restrictions.

Item 9.01 Financial Statements and Exhibits.

Forward Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, the expected impact of the COVID-19 pandemic on our operations and clinical trials, including on our Phase 1/2 trial for AGLE-177, the potential addressable markets of our product candidates, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

--------------------------------------------------------------------------------